GP VS TP in the Treatment of Advanced Nasopharyngeal Carcinoma in Northwest China

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Nasopharyngeal Squamous Cell CarcinomaToxicity Due to Radiotherapy
Interventions
DRUG

gemcitabine and cisplatin

Drug: gemcitabine and cisplatin The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.

DRUG

docetaxel and cisplatin

Drug: Docetaxel and cisplatin The TP regimen consists of docetaxel at a dose of 75 mg/m2/day on day 1,and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.

Trial Locations (1)

710032

Department of Radiation Oncology, Xijing Hospital, Fourth Military, Xi’an

All Listed Sponsors
lead

Air Force Military Medical University, China

OTHER

NCT01596868 - GP VS TP in the Treatment of Advanced Nasopharyngeal Carcinoma in Northwest China | Biotech Hunter | Biotech Hunter